ICAR-CMFRI develops anti-obesity medicine from seaweed

CadalminTM Antihypercholesterolemic, an anti-obesity nutraceutical product developed by ICAR-CMFRI.ICAR-Central Marine Fisheries Research Institute (CMFRI), Kochi has developed an anti-obesity nutraceutical from seaweeds. The product named CadalminTM Antihypercholesterolemic extract (CadalminTM ACe) is a natural remedy for obesity and dyslipidemia. ICAR-CMFRI scientists prepared the extract from seaweeds which are commonly available in the Indian coastal waters and are natural bounty of the sea and are known for their extraordinary medicinal properties.

Shri Justice P Sathasivam, Governor of Kerala, released the product during the inaugural ceremony of the Platinum Jubilee celebrations of the ICAR-CMFRI at the Headquarters in Kochi on 18th February 2017.

Bioactive pharmacophore leads from seaweeds were used to prepare the nutraceutical product.. CadalminTM Antihypercholesterolemic extract can be administered to regulate clinical indicators leading to dyslipidemia or obesity, total adipose tissue and visceral fat, triglycerides, cholesterol, both good and bad, known as HDL and LDL. The product contains 100% natural marine bioactive ingredients from selected seaweeds by a patented technology, and would be made available in 400 mg capsules.  

The nutraceutical does not have any side effects as established by detailed preclinical trials. CadalminTM Antihypercholesterolemic extract is the only product made by 100% natural marine bioactive ingredients from seaweeds as a natural remedy of obesity and dyslipidemia.  

The active ingredients in the product will be packed in plant-based capsules to meet the dietary needs of the large vegetarian population in India and abroad. CadalminTM Antihypercholesterolemic extract has a promising consumer appeal, and market potential especially for the large vegetarian population in India and abroad.

Large scale extraction of the active principles from the raw material was optimized in a factory unit. The total yield of the active principles from the raw material in the factory unit was found to be greater than 20%, which demonstrated the commercial feasibility of the nutraceutical product. The product is being out-licensed to a pharmaceutical company.  

4th Nutraceutical Product from ICAR-CMFRI

CadalminTM Antihypercholesterolemic extract is the fourth in the series of the nutraceutical products developed by the ICAR-CMFRI. Two anti-arthritic and one anti-diabetic nutraceutical products are the other three products developed by the institute in the past.  All these technologies have been commercialized through pharmaceutical companies.

(Source: ICAR-Central Marine Fisheries Research Institute, Kochi)